$193.40
4.962.63%
마지막 업데이트: Oct 14, 2:47 PM
Benzinga
Benzinga
Benzinga
수요일, 10월 14
Benzinga
© 2026 Benzinga | All Rights Reserved
Revolution Medicines (RVMD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-2.01 | $-1.84 | $-1.56 | $-1.40 |
| Actual | $-3.06 | $-2.29 | $-1.86 | $-1.61 |
| Surprise | -52.2% | -24.5% | -19.2% | -15.0% |
| Revenue | ||||
| Estimate | $39.7M | $6.1M | $11.6M | $6.0M |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | -100.0% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-2.37 | $-2.00 | $-1.80 | $-1.79 |
| Revenue | ||||
| Consensus | $25.6M | $153.4M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-3.06 | $-2.01 | -52.2 % |
| Q1 | May 6, 2026 | $-2.29 | $-1.84 | -24.5 % |
| Q4 | Feb 25, 2026 | $-1.86 | $-1.56 | -19.2 % |
| Q3 | Nov 5, 2025 | $-1.61 | $-1.40 | -15.0 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0 | $39.73M | -100.0 % |
| Q1 | May 6, 2026 | $0 | $6.10M | -100.0 % |
| Q4 | Feb 25, 2026 | $0 | $11.58M | -100.0 % |
| Q3 | Nov 5, 2025 | $0 | $6.01M | -100.0 % |